On October 26, 2025, Shenzhen Beimei Pharmaceutical Co., Ltd. (Beimei Pharma) successfully held a national investigator meeting for the Phase III clinical trial of TWYNEO^® (Tretinoin, Benzoyl Peroxide) in Hangzhou, marking the official launch of this pivotal Phase III study for Chinese acne patients.

Sponsored by Beimei Pharma, the study is led by Professor Wu Wenyu of Huashan Hospital Fudan University, and jointly conducted by 18 hospitals nationwide. Tigermed is providing professional clinical CRO services. More than 50 experts and scholars attended this investigator meeting, engaging in in-depth discussions and providing valuable suggestions for the TWYNEO^® clinical trial program.

（Photo：Professor Wu Wenyu of Huashan Hospital Fudan University）

In the opening speech, Ms. Wu Guangmei, Founder and Chairwoman of Beimei Pharma, expressed her sincere gratitude to the participating experts. She reviewed the history of TWYNEO^® and conveyed strong confidence in this Phase III clinical trial based on the positive data from overseas clinical studies, while also wishing for smooth collaboration among all parties in the future.

（Photo：Ms. Wu Guangmei, Founder and Chairwoman of Beimei Pharma）

In the speech, Prof. Wu Wenyu stated, "TWYNEO^® has overcome the difficulty in combining benzoyl peroxide and tretinoin through innovative microencapsulation technology, offering a promising new treatment option for acne patients in China. We look forward to the smooth progress and success of this study."

Tigermed and Beimei Pharma reported on the Phase III clinical trial protocol and US clinical trial data results respectively. Director Ma Ying of Huashan Hospital of Fudan University shared the key points and challenges in acne treatment and explained the IGA scoring rules and scoring requirements. Afterwards, all experts discussed and agreed on the key points of the study protocol, details of acne IGA scoring, and criteria for counting inflammatory/non-inflammatory lesions.

Dr. Ren Peng, Chief Technology Officer of Beimei Pharma, expressed heartfelt thanks to all participating experts. He emphasized that Beimei Pharma will fully support all clinical centers to ensure the smooth implementation of the TWYNEO^® clinical trial, and looks forward to providing a new treatment option for Chinese acne patients through close collaboration with the experts.

（Photo：Dr. Ren Peng, Chief Technology Officer of Beimei Pharma）

TWYNEO^® (Tretinoin, Benzoyl Peroxide) was approved for marketing in July 2021 in the United States.Beimei Pharma aquired the asset of TWYNEO^® in China (including Hong Kong, Macau, and Taiwan) and Israel on May 15th, 2024, including but not limited to patents, trademarks and domain names for product development, commercialization, and manufacture. 

TWYNEO^® is the first and only FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide cream for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. Benzoyl peroxide and tretinoin are both first-line treatment therapies for acne vulgaris. However, the two ingredients are prone to a chemical reaction when mixed, limiting the combined use, so the two ingredients require to be applied at different times of a day. In addition, using benzoyl peroxide or tretinoin alone may cause skin irritation, which also impacts the patient compliance. TWYNEO^® is the first breakthrough in using patented microencapsulation technology to solve the difficulty in combining benzoyl peroxide and tretinoin, and has in the history, for the first time accomplished the combination of the two active ingredients. The microencapsulation technology also relieves the skin irritation of topical benzoyl peroxide or tretinoin.

The American Academy of Dermatology's (AAD) 2024 updated and published Guidelines for the Management of Acne vulgaris, the classification, diagnosis, assessment, and treatment options for acne have been comprehensively updated. TWYNEO^® (the only topical cream that consists of a fixed-dose combination of tretinoin 0.1% and benzoyl peroxide 3%) is highly recommended for the treatment of acne patients 9 years of age and older.